Category: St. Jude Medical
A small European feasibility study of the Nanostim leadless pacemaker acquired by St. Jude Medical looks good at 3 months, according to a study published in the American Heart Assn. journal Circulation.
The Nanostim leadless pacemaker acquired by St. Jude Medical (NYSE:STJ) last year appeared safe and functional after 3 months, according to results of a small study published in the American Heart Assn. journal Circulation.
A new editorial in the Annals of Internal Medicine criticizes the premarket approval modification process, through which both Medtronic and St. Jude Medical released high-risk products that were later recalled.
The FDA grants pre-market approval to St. Jude Medical's Allure Quadra cardiac resynchronization therapy pacemaker.
St. Jude Medical (NYSE:STJ) said its Allure Quadra pacemaker will be the 1st on the U.S. market to offer quadripolar cardiac resynchronization therapy after the FDA granted pre-market approval to the device.
Here's a look at some of the top legal news stories for medical device companies this week.
St. Jude Medical says its Prodigy neurostimulation device won CE Mark approval in the European Union for a chronic pain indication.
St. Jude Medical (NYSE:STJ) said it's putting its Prodigy neurostimulation device on the market in Europe for patients with chronic back pain after winning CE Mark approval.
Volcano appeals a Delaware federal judge's dismissal of its lawsuit against St. Jude Medical over fractional flow reserve patents.
St. Jude Medical says it's launched a post-approval study in Europe for its Nanostim leadless pacemaker and performed the 1st implantations in a U.S. pivotal trial.
St. Jude Medical (NYSE:STJ) said it's enrolled the 1st patients in a post-approval trial of the Nanostim leadless pacemaker it acquired in October 2013.